- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07385443
Het Spaanse Nationale Register voor Myotone Dystrofie Type 1 (DM1-Hub)
Creación de un Nodo Integral Para la Distrofia Miotónica Tipo 1 en España: Registro clínico, Mapas genómicos, epigenómicos y proteómicos (DM1-Hub)
Myotonic Dystrophy Type 1 (DM1) is a rare genetic neuromuscular condition that can affect multiple organs and varies widely in how it presents. DM1 is the most common form of adult-onset muscular dystrophy, with an estimated prevalence of approximately 1-5 per 10,000 people. In Spain, the condition shows notable regional differences, making it especially important to understand its characteristics within the population.
The aim of this study is to support a research initiative designed to better characterise DM1. We are developing a comprehensive national registry, collecting patient-reported information, clinical data and omics data that will improve our understanding of the disease and help identify individuals who may be eligible for clinical trials.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
The DM1-Hub Patient Registry (https://www.dm1spain.com/) aims to recruit individuals living in Spain with a confirmed genetic diagnosis of myotonic dystrophy type 1 (DM1). Participants may be referred by healthcare professionals or patient organizations. They may also learn about the registry through outreach activities, informational materials, collaborations with national and local patient associations, DM1-Hub events, or through their own online searches.
After completing the informed consent process with their neurologist, participants are connected with the DM1-Hub patient support staff assigned to their hospital. An appointment is scheduled, and all the data collected is entered into the REDCap database.
The objective of this study is to establish a Natural History Patient Registry for individuals with DM1 in Spain. Participants will be invited to take part in follow-up assessments to support the characterization of disease progression over time. A parallel control group will also be recruited to facilitate biomarker discovery and improve understanding of factors associated with disease prognosis.
Studietype
Inschrijving (Geschat)
Contacten en locaties
Studiecontact
- Naam: Gisela Nogales Gadea, Ph.D.
- Telefoonnummer: (+34) 93 554 3050
- E-mail: gnogales@igtp.cat
Studie Contact Back-up
- Naam: Alvaro S Larran Mottino, Ph.D.
- E-mail: alarran@igtp.cat
Studie Locaties
-
-
Andalusia
-
Multiple Locations, Andalusia, Spanje
- Werving
- Hospitals within the DM1 network
-
Contact:
- Dr. Macarena Cabrera
- Telefoonnummer: (+34) 93 554 3050
- E-mail: dm1-hub@igtp.cat
-
Hoofdonderzoeker:
- Dr. Macarena Cabrera
-
-
Basque Country
-
Multiple Locations, Basque Country, Spanje
- Werving
- Hospitals within the DM1 network
-
Contact:
- Dr. Andone Sistiaga
- Telefoonnummer: (+34) 93 554 3050
- E-mail: dm1-hub@igtp.cat
-
Hoofdonderzoeker:
- Dr. Andone Sistiaga
-
-
Canary Islands
-
Multiple Locations, Canary Islands, Spanje
- Werving
- Hospitals within the DM1 network
-
Contact:
- Dr. Jorge Alonso
- Telefoonnummer: (+34) 93 554 3050
- E-mail: dm1-hub@igtp.cat
-
Hoofdonderzoeker:
- Dr. Jorge Alonso
-
-
Cantabria
-
Multiple Locations, Cantabria, Spanje
- Werving
- Hospitals within the DM1 network
-
Contact:
- Dr. Ana Lara Pelayo
- Telefoonnummer: (+34) 93 554 3050
- E-mail: dm1-hub@igtp.cat
-
Hoofdonderzoeker:
- Dr. Ana Lara Pelayo
-
-
Castilla-La Macha
-
Multiple Locations, Castilla-La Macha, Spanje
- Werving
- Hospitals within the DM1 network
-
Contact:
- Dr. Jorge García
- Telefoonnummer: (+34) 93 554 3050
- E-mail: dm1-hub@igtp.cat
-
Hoofdonderzoeker:
- Dr. Jorge García
-
-
Catalonia
-
Multiple Locations, Catalonia, Spanje
- Werving
- Hospitals within the DM1 network
-
Contact:
- Dr. Sebastián Figueroa
- Telefoonnummer: (+34) 93 554 3050
- E-mail: dm1-hub@igtp.cat
-
Hoofdonderzoeker:
- Dr. Sebastián Figueroa
-
-
Madrid
-
Multiple Locations, Madrid, Spanje
- Werving
- Hospitals within the DM1 network
-
Contact:
- Dr. Gerardo Gutiérrez
- Telefoonnummer: (+34) 93 554 3050
- E-mail: dm1-hub@igtp.cat
-
Hoofdonderzoeker:
- Dr. Gerardo Gutiérrez
-
-
Valencia
-
Multiple Locations, Valencia, Spanje
- Werving
- Hospitals within the DM1 network
-
Contact:
- Dr. Nuria Muelas
- Telefoonnummer: (+34) 93 554 3050
- E-mail: dm1-hub@igtp.cat
-
Hoofdonderzoeker:
- Dr. Nuria Muelas
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Kind
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Participants with Myotonic Dystrophy Type 1 (DM1) will volunteer to participate in this study. The study will be advertised through physician recommendations, outreach and educational activities directed at neuromuscular professionals, the registry website, national and local patient associations, and through patient-focused events, conferences, and scientific meetings across Spain.
Beschrijving
Inclusion Criteria:
- Confirmed diagnosis of Myotonic Dystrophy Type 1 (DM1) through genetic testing.
Exclusion Criteria:
- There are no exclusion criteria for the registry
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: COHORT
- Tijdsperspectieven: PROSPECTIVE
Cohorten en interventies
Groep / Cohort |
Interventie / Behandeling |
|---|---|
|
Myotonic Dystrophy Type 1 (DM1)
The group included Individuals with a confirmed genetic diagnosis of Myotonic Dystrophy Type 1 (DM1) |
Patient Registry |
|
Control
The group included control subjects as individuals without a genetic diagnosis of Myotonic Dystrophy Type 1 (DM1). |
Patient Registry |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Genomic Caracterization
Tijdsspanne: 1 year, year 1
|
Long-read genomic sequencing analyses encompassing CTG expansion characterization and whole-genome genetic and epigenetic profiling. |
1 year, year 1
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Proteomic Characterization
Tijdsspanne: 1 year, year 1
|
Biomarker evaluation |
1 year, year 1
|
|
WAIS IV neuropsychological tests
Tijdsspanne: 2 years, year 1
|
IQ, memory, attention, language |
2 years, year 1
|
|
vHOT
Tijdsspanne: 1 year, year 1
|
Video Hand Opening Time, clinical measure for Myotonic Dystrophy (DM1) tracking hand reopening speed |
1 year, year 1
|
|
Muscular Impairment Rating Scale (MIRS)
Tijdsspanne: 1 year, year 1
|
The Muscular Impairment Rating Scale is a 5-point ordinal clinical scale used to evaluate the severity of muscular impairment in patients with myotonic dystrophy. Scores range from 1 (minimal or no impairment) to 5 (severe muscle impairment). Higher scores indicate worse functional impairment. |
1 year, year 1
|
|
Hand Grip Strength
Tijdsspanne: 1 year, year 1
|
Hand grip strength is assessed as a measure of upper limb muscle strength using a hand-held dynamometer. Grip strength is measured separately in the dominant and non-dominant hand, and recorded in kilograms (kg). For each hand, three consecutive attempts are performed, alternating between hands to minimize fatigue. The maximum value (best of three attempts) for each hand is recorded and used for analysis. Higher values indicate better muscle strength and functional outcome, while lower values reflect greater muscular impairment. |
1 year, year 1
|
|
6MWT
Tijdsspanne: 1 year, year 1
|
Six-Minute Walk Test |
1 year, year 1
|
|
10MWRT
Tijdsspanne: 1 year, year 1
|
10-meter Walk/Run Test |
1 year, year 1
|
|
30CST
Tijdsspanne: 1 year, year 1
|
30-Second Chair Stand Test |
1 year, year 1
|
|
FVC
Tijdsspanne: 1 year, year 1
|
Forced Vital Capacity (L) |
1 year, year 1
|
|
Electrocardiogram (ECG)
Tijdsspanne: 1 year, year 1
|
The following ECG-derived parameters and abnormalities are recorded:
All measurements are extracted from the ECG tracing according to standard clinical practice. Higher PR or QRS durations and the presence of conduction abnormalities or arrhythmias indicate greater cardiac involvement, while normal values and absence of abnormalities indicate preserved cardiac electrical function. |
1 year, year 1
|
|
BMI
Tijdsspanne: 1 year, year 1
|
Body Mass Index |
1 year, year 1
|
|
OBGYN events
Tijdsspanne: 1 year, year 1
|
Collection of gynecological clinical history and relevant reproductive health events for participants who opt to provide this information. |
1 year, year 1
|
|
GI symptomatology
Tijdsspanne: 1 year, year 1
|
Collection of participant-reported gastrointestinal symptoms and related clinical information. |
1 year, year 1
|
|
MBS (Myotonia Behaviour Scale)
Tijdsspanne: 1 year, year 1
|
Myotonia severity is assessed using the Myotonia Behaviour Scale (MBS), a clinician-reported ordinal scale that evaluates the functional impact of myotonia-related muscle stiffness on daily activities. The scale ranges from 0 to 5, with higher scores indicating greater severity and functional interference due to myotonia: 0: No muscle stiffness
Lower scores reflect minimal or absent myotonia, while higher scores reflect greater functional impairment due to myotonia. |
1 year, year 1
|
|
Modified Rankin Scale (mRS)
Tijdsspanne: 1 year, year 1
|
Global disability is assessed using the Modified Rankin Scale (mRS), a widely used ordinal scale measuring the degree of disability or dependence in daily activities. The scale ranges from 0 to 6, with higher scores indicating greater disability or death: 0: No symptoms
|
1 year, year 1
|
|
Patient-Reported Outcome: Quality of life
Tijdsspanne: 1 year, year 1
|
INQoL (Individualized Neuromuscular Quality of Life Questionnaire) |
1 year, year 1
|
|
Patient-Reported Outcome: Fatigue
Tijdsspanne: 1 year, year 1
|
FSS (Fatigue Severity Scale ) |
1 year, year 1
|
|
Patient-Reported Outcome: Dietary Habits
Tijdsspanne: 1 year, year 1
|
MEDAS-14 (Mediterranean Diet Adherence Screener) |
1 year, year 1
|
|
Patient-Reported Outcome: Sleepiness
Tijdsspanne: 1 year, year 1
|
DSS (Daytime Sleepiness Scale) |
1 year, year 1
|
|
Patient-Reported Outcome: Apathy
Tijdsspanne: 1 year, year 1
|
AES (Apathy Evaluation Scale) |
1 year, year 1
|
|
Patient-Reported Outcome: Physical Activity
Tijdsspanne: 1 year, year 1
|
IPAQ (International Physical Activity Questionnaire) |
1 year, year 1
|
|
Patient-Reported Outcome: Mental Health
Tijdsspanne: 1 year, year 1
|
MHI-5 (Mental Health Inventory) |
1 year, year 1
|
Medewerkers en onderzoekers
Medewerkers
Onderzoekers
- Studie directeur: Gisela Nogales Gadea, Ph.D., Germans Trias i Pujol Research Institute
- Hoofdonderzoeker: Arturo Lopez Castel, Ph.D., INCLIVA Instituto de Investigación Sanitaria
- Hoofdonderzoeker: Virginia Arechavala-Gomeza, Ph.D., IIS Biobizkaia
Publicaties en nuttige links
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Musculoskeletale aandoeningen
- Ziekten van het zenuwstelsel
- Spierziekten
- Neuromusculaire aandoeningen
- Genetische ziekten, aangeboren
- Neurodegeneratieve ziekten
- Heredodegeneratieve aandoeningen, zenuwstelsel
- Spieraandoeningen, atrofisch
- Spierdystrofieën
- Myotone aandoeningen
- Aangeboren, erfelijke en neonatale ziekten en afwijkingen
- Myotone dystrofie
Andere studie-ID-nummers
- PMPER24/00007
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .